Argenx
ARGX
#591
Rank
$34.20 B
Marketcap
$562.82
Share price
-5.41%
Change (1 day)
14.91%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Argenx (ARGX) - Cash on Hand

Cash on Hand as of June 2024 : $3.10 Billion USD

According to Argenx 's latest financial reports the company has $3.10 Billion USD in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Argenx - Cash on Hand chart (from 2021 to 2020)

Cash on Hand by year

Year Cash on Hand Change
2022-12-31$2.19 B-6.17%
2021-12-31$2.33 B-4.84%
2020-12-31$2.45 B46.07%
2019-12-31$1.68 B127.54%
2018-12-31$0.73 B42.66%
2017-12-31$0.51 B383.99%
2016-12-31$0.10 B111.48%
2015-12-31$50.59 M-38.88%
2014-12-31$82.77 M86.94%
2013-12-31$44.28 M53.59%
2012-12-31$28.82 M-27.25%
2011-12-31$39.62 M183.71%
2010-12-31$13.96 M